1. Home
  2. RGEN vs HALO Comparison

RGEN vs HALO Comparison

Compare RGEN & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGEN
  • HALO
  • Stock Information
  • Founded
  • RGEN 1981
  • HALO 1998
  • Country
  • RGEN United States
  • HALO United States
  • Employees
  • RGEN N/A
  • HALO N/A
  • Industry
  • RGEN Medical/Dental Instruments
  • HALO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • RGEN Health Care
  • HALO Health Care
  • Exchange
  • RGEN Nasdaq
  • HALO Nasdaq
  • Market Cap
  • RGEN 9.1B
  • HALO 7.3B
  • IPO Year
  • RGEN N/A
  • HALO N/A
  • Fundamental
  • Price
  • RGEN $158.99
  • HALO $57.75
  • Analyst Decision
  • RGEN Buy
  • HALO Buy
  • Analyst Count
  • RGEN 11
  • HALO 9
  • Target Price
  • RGEN $180.63
  • HALO $62.78
  • AVG Volume (30 Days)
  • RGEN 652.6K
  • HALO 1.1M
  • Earning Date
  • RGEN 02-20-2025
  • HALO 02-18-2025
  • Dividend Yield
  • RGEN N/A
  • HALO N/A
  • EPS Growth
  • RGEN N/A
  • HALO 63.33
  • EPS
  • RGEN N/A
  • HALO 3.43
  • Revenue
  • RGEN $634,439,000.00
  • HALO $1,015,324,000.00
  • Revenue This Year
  • RGEN $2.28
  • HALO $23.48
  • Revenue Next Year
  • RGEN $9.69
  • HALO $18.16
  • P/E Ratio
  • RGEN N/A
  • HALO $16.84
  • Revenue Growth
  • RGEN 0.33
  • HALO 22.44
  • 52 Week Low
  • RGEN $113.50
  • HALO $37.73
  • 52 Week High
  • RGEN $203.13
  • HALO $65.53
  • Technical
  • Relative Strength Index (RSI)
  • RGEN 53.41
  • HALO 62.93
  • Support Level
  • RGEN $143.83
  • HALO $56.07
  • Resistance Level
  • RGEN $169.00
  • HALO $60.67
  • Average True Range (ATR)
  • RGEN 5.95
  • HALO 1.43
  • MACD
  • RGEN -0.24
  • HALO -0.22
  • Stochastic Oscillator
  • RGEN 61.46
  • HALO 48.86

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Share on Social Networks: